**Author details**

Shailendra K. Saxena1 \*, Vimal K. Maurya1 , Saniya Ansari1 , Swatantra Kumar1 , Shivani Maurya1 , Ankur Gupta<sup>2</sup> , Anil K. Tripathi1 and Bipin Puri1

1 Centre for Advanced Research (CFAR), Faculty of Medicine, King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India

2 Government Pharmacy College, Sajong, Rumtek, Sikkim, India

\*Address all correspondence to: shailen@kgmcindia.edu

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Introductory Chapter: High-Throughput Screening - A New Tool for Precision Medicine DOI: http://dx.doi.org/10.5772/intechopen.104456*

## **References**

[1] Szymański P, Markowicz M, Mikiciuk-Olasik E. Adaptation of high-throughput screening in drug discovery-toxicological screening tests. International Journal of Molecular Sciences. 2012;**13**(1):427-452. DOI: 10.3390/ijms13010427

[2] Sachinidis A. High-throughput base editing: A promising technology for precision medicine and drug discovery. Signal Transduction and Targeted Therapy. 2021;**6**(1):221. DOI: 10.1038/ s41392-021-00633-0

[3] Maurya VK, Kumar S, Prasad AK, Bhatt MLB, Saxena SK. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor. VirusDisease. 2020;**31**(2):179- 193. DOI: 10.1007/s13337-020-00598-8

[4] Maurya VK, Kumar S, Bhatt MLB, Saxena SK. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection. Journal of Biomolecular Structure and Dynamics. 2022;**40**(4):1719-1735. DOI: 10.1080/07391102.2020.1832577

[5] Mishra S, Maurya VK, Kumar S, Ankita KA, Saxena SK. Clinical management and therapeutic strategies for the thyroid-associated Ophthalmopathy: Current and future perspectives. Current Eye Research. 2020;**45**(11):1325-1341. DOI: 10.1080/ 02713683.2020.1776331

[6] Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019 nCoV) and SARS coronavirus (SARS-CoV). VirusDisease. 2020;**31**(1):13-21. DOI: 10.1007/s13337-020-00571-5

[7] Aldewachi H, Al-Zidan RN, Conner MT, Salman MM. Highthroughput screening platforms in the discovery of novel drugs for neurodegenerative diseases. Bioengineering (Basel). 2021;**8**(2):30. DOI: 10.3390/bioengineering8020030

[8] Shinn P, Chen L, Ferrer M, et al. High-throughput screening for drug combinations. Methods in Molecular Biology. 2019;**1939**:11-35. DOI: 10.1007/978-1-4939-9089-4\_2

[9] Gorshkov K, Chen CZ, Marshall RE, et al. Advancing precision medicine with personalized drug screening. Drug Discovery Today. 2019;**24**(1):272-278. DOI: 10.1016/j.drudis.2018.08.010

[10] Trombetta RP, Dunman PM, Schwarz EM, Kates SL, Awad HA. A high-throughput screening approach to repurpose FDA-approved drugs for bactericidal applications against staphylococcus aureus small-colony variants. mSphere. 2018;**3**(5): e00422-e00418. DOI: 10.1128/mSphere. 00422-18

[11] Williams JR, Lorenzo D, Salerno J, Yeh VM, Mitrani VB, Kripalani S. Current applications of precision medicine: A bibliometric analysis. Personalized Medicine. 2019;**16**(4): 351-359. DOI: 10.2217/pme-2018-0089

[12] Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nature Reviews Materials. 2021;**6**(4):351-370. DOI: 10.1038/s41578-020-00269-6

[13] Collins H, Calvo S, Greenberg K, Forman Neall L, Morrison S. Information needs in the precision medicine era: How genetics home reference can help. Interactive Journal of Medical Research. 2016;**5**(2):e13. DOI: 10.2196/ijmr.5199

[14] Lightbody G, Haberland V, Browne F, et al. Review of applications of high-throughput sequencing in personalized medicine: Barriers and facilitators of future progress in research and clinical application. Briefings in Bioinformatics. 2019;**20**(5):1795-1811. DOI: 10.1093/bib/bby051

[15] Alterovitz G, Dean D, Goble C, et al. Enabling precision medicine via standard communication of HTS provenance, analysis, and results. PLoS Biology. 2018;**16**(12):e3000099. DOI: 10.1371/journal.pbio.3000099

[16] Jameson JL, Longo DL. Precision medicine—Personalized, problematic, and promising. The New England Journal of Medicine. 2015;**372**(23):2229- 2234. DOI: 10.1056/NEJMsb1503104

[17] Phan N, Hong JJ, Tofig B, et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumororganoids. Communications Biology. 2019;**2**:78. DOI: 10.1038/s42003-019-0305-x

[18] Wang ZG, Zhang L, Zhao WJ. Definition and application of precision medicine. Chinese Journal of Traumatology. 2016;**19**(5):249-250. DOI: 10.1016/j.cjtee.2016.04.005

[19] Hasanzad M, Sarhangi N, AghaeiMeybodi HR, Nikfar S, Khatami F, Larijani B. Precision medicine in non communicable diseases. International Journal of Molecular and Cellular Medicine. 2019;**8**(Suppl1):1-18. DOI: 10.22088/ IJMCM.BUMS.8.2.1

[20] Wang C, Xu P, Zhang L, Huang J, Zhu K, Luo C. Current strategies and applications for precision drug design. Frontiers in Pharmacology. 2018;**9**:787. DOI: 10.3389/fphar.2018.00787

[21] Taylor JY, Barcelona de Mendoza V. Improving -omics-based research and precision health in minority populations: Recommendations for nurse scientists. Journal of Nursing

Scholarship. 2018;**50**(1):11-19. DOI: 10.1111/jnu.12358

[22] Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;**148**(6):1293- 1307. DOI: 10.1016/j.cell.2012.02.009

[23] Rehm HL. Disease-targeted sequencing: A cornerstone in the clinic. Nature Reviews. Genetics. 2013;**14**(4):295-300. DOI: 10.1038/ nrg3463

[24] Shyr D, Liu Q. Next generation sequencing in cancer research and clinical application. Biological Procedures Online. 2013;**15**(1):4. DOI: 10.1186/1480-9222-15-4

[25] Reuter JA, Spacek DV, Snyder MP. High-throughput sequencing technologies. Molecular Cell. 2015;**58**(4):586-597. DOI: 10.1016/j. molcel.2015.05.004

[26] Nussinov R, Jang H, Tsai CJ, Cheng F. Correction: Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. PLoSComputational Biology. 2019;**15**(6):e1007114. DOI: 10.1371/ journal.pcbi.1007114

[27] Zhu S, Rooney S, Michlewski G. RNA-targeted therapies and highthroughput screening methods. International Journal of Molecular Sciences. 2020;**21**(8):2996. DOI: 10.3390/ijms21082996

[28] Azarian T, Cook RL, Johnson JA, et al. Whole-genome sequencing for outbreak investigations of methicillinresistant Staphylococcus aureus in the neonatal intensive care unit: Time for routine practice? Infection Control and Hospital Epidemiology. 2015;**36**(7): 777-785. DOI: 10.1017/ice.2015.73

*Introductory Chapter: High-Throughput Screening - A New Tool for Precision Medicine DOI: http://dx.doi.org/10.5772/intechopen.104456*

[29] Putignani L, Gasbarrini A, Dallapiccola B. Potential of multiomics technology in precision medicine. Current Opinion in Gastroenterology. 2019;**35**(6):491-498. DOI: 10.1097/ MOG.0000000000000589

[30] Centers for disease control and prevention (CDC). Infectious Diseases: Precision Medicine for Public Health. 2022. https://blogs.cdc.gov/genomics/ 2015/09/24/infectious-diseases/ [Accessed: January 30, 2022]

[31] Lange C, Aarnoutse R, Chesov D, et al. Perspective for precision medicine for tuberculosis. Frontiers in Immunology. 2020;**11**:566608. DOI: 10.3389/fimmu.2020.566608

[32] Leguia M, Vila-Sanjurjo A, Chain PSG, Berry IM, Jarman RG, Pollett S. Precision medicine and precision public health in the era of pathogen next-generation sequencing. The Journal of Infectious Diseases. 2020;**221**(Suppl 3): S289-S291. DOI: 10.1093/infdis/jiz424

[33] Coffey DG, Cowan AJ, DeGraaff B, et al. High-throughput drug screening and multi-omic analysis to guide individualized treatment for multiple myeloma. JCO Precision Oncology. 2021;**5**:PO.20.00442. DOI: 10.1200/ PO.20.00442

[34] Quartararo CE, Reznik E, deCarvalho AC, Mikkelsen T, Stockwell BR. High-throughput screening of patient-derived cultures reveals potential for precision medicine in glioblastoma. ACS Medical Chemistry Letters. 2015;**6**(8):948-952. DOI: 10.1021/acsmedchemlett.5b00128

[35] Tsoli M, Wadham C, Pinese M, et al. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. Cancer Biology and Therapy. 2018;**19**(12): 1078-1087. DOI: 10.1080/15384047.2018. 1491498
